Market Cap : 1.38 B | Enterprise Value : 1.21 B | P/E (TTM) : | P/B : 7.15 |
---|
NAS:ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 235.07 |
61% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. ZLAB: 235.07 ) Ranked among companies with meaningful Cash-to-Debt only. |
ZLAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 235.07 Med: No Debt Max: No Debt Current: 235.07 |
Debt-to-EBITDA | -0.01 |
99.99% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 2.04 vs. ZLAB: -0.01 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
ZLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.01 Med: 0 Max: 0 Current: -0.01 |
Interest Coverage | No Debt |
52% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. ZLAB: No Debt ) Ranked among companies with meaningful Interest Coverage only. |
ZLAB'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt Current: No Debt |
Piotroski F-Score: 5 |
|
Altman Z-Score: 55.66 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
ROE % | -55.76 |
82% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. ZLAB: -55.76 ) Ranked among companies with meaningful ROE % only. |
ZLAB'
s ROE % Range Over the Past 10 Years
Min: -55.76 Med: 0 Max: 0 Current: -55.76 |
ROA % | -35.86 |
50% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. ZLAB: -35.86 ) Ranked among companies with meaningful ROA % only. |
ZLAB'
s ROA % Range Over the Past 10 Years
Min: -129.28 Med: -101.12 Max: -35.86 Current: -35.86 |
ROC (Joel Greenblatt) % | -527.62 |
55% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. ZLAB: -527.62 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
ZLAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3943.6 Med: -3126.39 Max: -527.62 Current: -527.62 |
George Soros 17,500 sh (New) Steven Cohen 50,000 sh (New) Ron Baron 1,900,431 sh (+1955.83%) |
Jim Simons 22,000 sh (New) Ron Baron 1,974,013 sh (+3.87%) | Steven Cohen Sold Out George Soros Sold Out |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
---|
Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
---|---|---|
Compare: | ROCO:4174, XMCE:ROVI, NAS:MGNX, OCSE:BAVA, SHSE:603566, SZSE:002022, XKRX:078160, NAS:NTLA, SHSE:603718, XKRX:003000, SZSE:002872, NAS:BOLD, NAS:ACOR, NAS:ADAP, NAS:RVNC, SZSE:300149, SAU:2070, SHSE:600200, OSTO:HMED, TSXV:CRON » details | |
Traded in other countries: | 1ZL.Germany, | |
Headquarter Location: | China |
vs
industry |
vs
history |
||
---|---|---|---|
PB Ratio | 7.15 |
54% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. ZLAB: 7.15 ) Ranked among companies with meaningful PB Ratio only. |
ZLAB'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 8.15 Current: 7.15 |
EV-to-EBIT | -23.48 |
99.99% of the 261 Companies in the Global Biotechnology industry. ( Industry Median: 22.17 vs. ZLAB: -23.48 ) Ranked among companies with meaningful EV-to-EBIT only. |
ZLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -27.32 Med: 0 Max: 0 Current: -23.48 |
EV-to-EBITDA | -23.72 |
99.99% of the 281 Companies in the Global Biotechnology industry. ( Industry Median: 18.08 vs. ZLAB: -23.72 ) Ranked among companies with meaningful EV-to-EBITDA only. |
ZLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.62 Med: 0 Max: 0 Current: -23.72 |
Current Ratio | 17.78 |
90% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. ZLAB: 17.78 ) Ranked among companies with meaningful Current Ratio only. |
ZLAB'
s Current Ratio Range Over the Past 10 Years
Min: 3.36 Med: 16.26 Max: 19.11 Current: 17.78 |
Quick Ratio | 17.78 |
91% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. ZLAB: 17.78 ) Ranked among companies with meaningful Quick Ratio only. |
ZLAB'
s Quick Ratio Range Over the Past 10 Years
Min: 3.36 Med: 16.26 Max: 19.11 Current: 17.78 |
vs
industry |
vs
history |
---|
vs
industry |
vs
history |
||
---|---|---|---|
Price-to-Net-Cash | 8.55 |
63% of the 613 Companies in the Global Biotechnology industry. ( Industry Median: 7.29 vs. ZLAB: 8.55 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
ZLAB'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.93 Med: 6.01 Max: 9.03 Current: 8.55 |
Price-to-Net-Current-Asset-Value | 8.32 |
61% of the 745 Companies in the Global Biotechnology industry. ( Industry Median: 6.45 vs. ZLAB: 8.32 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
ZLAB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.9 Med: 5.9 Max: 8.79 Current: 8.32 |
Price-to-Tangible-Book | 7.14 |
54% of the 894 Companies in the Global Biotechnology industry. ( Industry Median: 5.32 vs. ZLAB: 7.14 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
ZLAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.51 Med: 5.21 Max: 7.54 Current: 7.14 |
Earnings Yield (Greenblatt) % | -4.26 |
55% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. ZLAB: -4.26 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
ZLAB'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.54 Med: 0 Max: 0 Current: -4.26 |
EPS (TTM) $ | -1.35 |
---|---|
Volatility | 53.57% |
52-Week Range $ | 14.29 - 33.86 |
Shares Outstanding (Mil) | 50.61 |
Dec18 | Dec19 | Dec20 | |
---|---|---|---|
Revenue (Mil $) | 17 | 49 | |
EBIT (Mil $) | -55 | -62 | -66 |
EBITDA (Mil $) | -53 | -58 | -60 |
EPS ($) | -0.96 | -0.96 | -1.05 |
EPS without NRI ($) | -0.96 | -0.96 | -1.05 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
Dividends per Share ($) |
|
GF Chat